BRCA mutation status and olaparib-related toxicity during maintenance therapy: a real-world retrospective cohort study.

Front Oncol · 2026 · PMC13070956 · PMID 41982234

Europe PMC DOI

hedged sentence

0.0940

closest p · 1.9× alpha

0.0940

boldest claim

The sentences

did not reach statistical significancep = 0.094so close (0.05 < p ≤ 0.1)

Overall, 22 of 24 patients (91.7%) in the BRCA-mutant group and 11 of 16 patients (68.8%) in the BRCA wild-type group experienced at least one olaparib-related adverse event of any grade during treatment, although this difference did not reach statistical significance (OR 5.00, 95% CI 0.78–27.08; p = 0.094).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.